Carolina Schinke, MD, of the University of Arkansas for Medical Sciences, discusses results from the pivotal phase II MonumenTAL-1 trial during the 2023 American Society of Clinical Oncology Annual Meeting.
The study evaluated talquetamab, a bispecific antibody targeting GPRC5D and CD3, in patients with relapsed or refractory multiple myeloma.
In this video, Dr. Schinke speaks about the study’s safety and efficacy findings, how talquetamab can address unmet needs in this population of patients, and what she sees as the next steps.
The response rates seen with talquetamab in the trial were “very impressive,” Dr. Schinke said.
“In cohort A and cohort B, the response rates were around 70%, which I think is really exceptional for a single agent,” she said. “Even in cohort C, those patients that had prior T-cell redirecting treatment, the overall response rate was 65%, so still also very good. I think that’s very encouraging for these patients that there are still options available that previously were not.”